Similarly, the PRODIGE 4/ACCORD 11 randomized trial observed a trend toward longer median OS in female patients with metastatic disease receiving FOLFIRINOX, although this did not reach statistical significance ( 64 ).
← all excerpts
<p>Unveiling sex differences in pancreatic ductal adenocarcinoma: Current evidence and future directions (Review)</p>.
1
—
—